Targeting protein kinases in cancer therapy: a success?
The fundamental role of kinases in cancer progression has promoted the development of a plethora of therapeutic inhibitors. Despite the promise of effective treatment with little associated toxicity, the clinical experience with these agents has been mixed. This review will summarize recent advances made in the development of kinase inhibitors to highlight emerging issues and the strategies by which they being addressed.
Pearson
Mark A
MA
Novartis Institutes for Biomedical Research Basel, Oncology, Novartis Pharma AG, WKL.125.4.16, CH-4002, Basel, Switzerland. mark_andrew.pearson@pharma.novartis.com
Fabbro
Doriano
D
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000503:physiopathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors